SENSICARDIAC vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SENSICARDIAC

by Diacoustic Medical Devices (Pty) Ltd.

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

SENSICARDIAC is designed for real-time heart murmur detection and classification using electronic stethoscopes, aiding in immediate diagnostic decisions and referral management. In contrast, Tempus ECG-AF utilizes 12-lead ECG analysis to identify patients aged 65 or older at increased risk of developing atrial fibrillation within the next year, focusing on proactive risk stratification. Therefore, while both are cardiology AI tools, they serve distinct clinical purposes and utilize different data inputs.

Choose SENSICARDIAC if…

Choose SENSICARDIAC if your practice requires real-time, AI-powered heart murmur detection during auscultation, particularly for remote cardiac care or telehealth scenarios. This tool is ideal for physicians needing to quickly classify murmurs as pathological or physiological, aiding in immediate diagnostic decisions and reducing unnecessary specialist referrals.

View SENSICARDIAC →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based algorithm is best suited for integrating into existing cardiology workflows to enhance risk stratification and guide earlier follow-up for preventative care.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SENSICARDIAC	Tempus ECG-AF
Pricing	Unknown	Contact vendor
Deployment	SensiCardiac is a software package running on a Windows PC that interfaces with compatible electronic stethoscopes. SensiCardiac Mobi runs on a mobile device (iPhone 4S or later) and interfaces with a hosted Linux server environment. The related Telesensi platform operates entirely in the browser.	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SENSICARDIAC

SENSICARDIAC (Tool A) offers a guided auscultation process and real-time analysis with electronic stethoscopes, suggesting a more interactive and intuitive user experience at the point of care. Its cloud and desktop deployment options also provide flexibility for clinicians.

Clinical Value

Tempus ECG-AF

Tempus ECG-AF (Tool B) is an FDA-cleared algorithm that identifies patients at increased risk of developing Atrial Fibrillation within 12 months, enabling proactive intervention and earlier follow-up. This predictive capability for a serious condition in a high-risk population offers a significant clinical advantage in preventative care.

Pricing & Value

Tempus ECG-AF

While both tools require direct contact for pricing, Tempus ECG-AF (Tool B) explicitly provides information on CMS reimbursement codes and a Medicare rate. This transparency regarding potential reimbursement significantly enhances its value proposition for healthcare providers by outlining a path for cost recovery.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF (Tool B) is described as a software solution integrated into healthcare facility systems and is compatible with major ECG vendors like GE and Philips. This deep integration into existing cardiology workflows and infrastructure makes it highly suitable for large-scale enterprise deployment.

Innovation

Tempus ECG-AF

Tempus ECG-AF (Tool B)'s ability to predict the future risk of Atrial Fibrillation from a standard 12-lead ECG represents a significant innovation in preventative precision medicine. This proactive risk stratification goes beyond immediate diagnosis, offering a transformative approach to patient care.

Support & Docs

Tie

Neither SENSICARDIAC (Tool A) nor Tempus ECG-AF (Tool B) provides specific details on support channels, service level agreements, or comprehensive documentation within the provided facts. Without further comparable information, it is not possible to definitively distinguish between the two offerings in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SENSICARDIAC	Tempus ECG-AF
Name	SENSICARDIAC	Tempus ECG-AF
Company	DIACOUSTIC MEDICAL (PTY)	Tempus AI, Inc.
Primary Function	AI-powered, cloud-based heart murmur detection service that classifies murmurs as pathological or physiological.	AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Integration	Electronic stethoscopes (e.g., 3M Littmannu00ae 3200)	FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems
Target Patient Population	Not specified	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery
Specialties	Cardiology, Internal Medicine, Pediatrics	Cardiology, Geriatrics, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring SENSICARDIAC and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do SENSICARDIAC and Tempus ECG-AF integrate into a physician's existing clinical workflow and what are their primary clinical applications?

SENSICARDIAC integrates with electronic stethoscopes for real-time heart murmur detection during auscultation, classifying murmurs as pathological or physiological to aid diagnosis and potentially reduce unnecessary referrals. Tempus ECG-AF analyzes existing 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation within the next 12 months, supporting earlier identification and follow-up within the standard ECG interpretation workflow.

What is the depth of EHR integration for each tool, and how are results recorded and accessed?

SENSICARDIAC generates detailed cardiac reports as downloadable PDFs, which can then be incorporated into a patient's EHR. Tempus ECG-AF is designed to be integrated into healthcare facility systems and is compatible with FDA-authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems, suggesting a more direct data flow for results.

What specific metrics or validation studies support the accuracy and reliability of each tool's AI analysis?

SENSICARDIAC classifies murmurs based on analysis against a large validated database of pathological heart murmurs. Tempus ECG-AF's algorithm was trained on over 1.5 million ECGs from more than 500,000 patients to predict AF risk, with results intended for interpretation alongside other diagnostic information and clinical history.

How do the target specialties and patient populations differ between SENSICARDIAC and Tempus ECG-AF?

SENSICARDIAC primarily targets Cardiology, Internal Medicine, and Pediatrics for general heart murmur detection across various age groups. Tempus ECG-AF focuses on Cardiology, Geriatrics, and Internal Medicine, specifically for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

What is the expected learning curve for physicians to effectively use and interpret the results from each AI tool?

SENSICARDIAC features a guided auscultation process to assist users, with the AI providing clear classifications (Class I: dangerous pathological, Class III: innocent physiological) in detailed reports. Tempus ECG-AF requires physicians to interpret the AI-generated risk assessment in conjunction with other diagnostic information and the patient's full clinical history.

What are the key considerations for deploying each tool across multiple clinical sites or a larger healthcare system?

SENSICARDIAC, as a cloud-based service with a desktop application, offers flexibility for deployment across various sites, requiring integration with electronic stethoscopes. Tempus ECG-AF is deployed as a software solution integrated into healthcare facility systems, implying a more structured rollout process to ensure compatibility with existing cardiology infrastructure.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring SENSICARDIAC or Tempus ECG-AF

Backers

Who funded each tool's parent company.